CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotech company employing its proprietary transformer Base Editor (tBE) to pioneer next-generation gene editing therapies.
Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing β-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrate its superior performance, indicating significant potential for CS-101 to become a best-in-class gene editing therapy for curing patients with β-hemoglobinopathies.
Proof-of-concept (POC) data in mice for in vivo pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases.
Ex vivo multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function in vivo compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development.
tBE offers significant advantages in controlling off-target effects and enhancing in vivo editing efficiency, making it ideal for both multiplex editing and precise single-target editing. It is compatible with various delivery system, including ex vivo editing in hematopoietic stem cells (HSCs) and T cells, as well as in vivo editing via LNPs or adeno-associated viruses (AAVs).
We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases.
Our focus on biotechnology innovation, research and development underscores our commitment to providing efficient, reliable and safe solution for unmet medical needs.
CorrectSequence Therapeutics has gathered dozens of outstanding biomedical experts from the fields of R&D, new drug development, CMC development, clinical operation, quality, etc. The management team and R&D team have more than 10 years industrial experience, with more than 40% of the staff holding master degrees.
Staffs of our management team and R&D team come from well-known domestic and international pharmaceutical companies, research institutions and drug regulatory authorities, such as USA FDA, Merck (MSD US), Pfizer (US), Roche China, Novartis China, Henlius, Luye Pharma, Sinopharm, WuXi Biologics, WuXi AppTech, JW Therapeutics, Hengrui, Innovent, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, etc. We have cross-field drug R&D experience with cancer, genetic disease, liver disease, blood disease, infectious disease, rare disease, mRNA therapy, CAR-T therapy, TCR-T therapy, monoclonal antibody therapy, stem cell therapy and tumor immunotherapy, etc.
Industrial Experience
10 Years+
Management Team and R&D Team
Proportion of M.D.
65% +
Management Team and R&D Team
Xiaodun (Susan) Mou, Ph.D.
Chief Executive Officer
Li Bin, Ph.D.
Distinguished Adviser
Jia Chen, Ph.D.
Distinguished Scientific Adviser
Li Yang, Ph.D.
Distinguished Scientific Adviser
Hao Yin, Ph.D.
Distinguished Scientific Adviser
Bei Yang, Ph.D.
Distinguished Scientific Adviser
2024.09Dr. Xiaodun Mou, CEO of Correctseq, won the Bronze Prize of the 4th "Haiju Talents" Global Innovation and Entrepreneurship Competition
2024.09Excellence Award in the 2024 National Disruptive Technology Innovation Competition
2024.01Dr. Lijie Wang, head of Science Innovation of Correctseq, won the nomination award of "Shanghai Science and Technology Youth 35 Leadership Program" in 2023
2023.112023 Shanghai High Value Patent Operation Competition Top 20 & Patent Operation Benchmark Award
2023.10A winning project in the "Digital Age: International Trends in Precision Medicine and Chinese Innovation" project roadshow
2023.10Chinese Healthcare Front-Runners Top 100 (IBIWS)
2022.12tBE (transformer Base Editor) won the 19th People's Ingenuity Award
2022.122022 Science and technology excellence Award of Jiading District, Shanghai
2022.11Dr. Xiaodun Mou was Selected as the Annual Influential Enterprise Leaders of Chinese CGT Field in 2022
2022.10Venture Capital Star of Shanghai Entrepreneurs Association & Simbay Park
2022.092022 Biomedical "Rising Star" in First Season
2022.06Top 10 Gene Therapy Companies of 2022 Future Healthcare VB100-Best Performing Companies in Value Fields (VBDATA.CN)
2022.062022 Top 50 Biotech Innovation Companies (KPMG)
2022.02TOP 50 Innovation and Development Companies of 2022 Jiading District’s Stabilizing Business and Promoting Investment project
2022.01Professor Jia Chen was Selected as "Outstanding Innovation and Entrepreneurial Talent of Zhangjiang”
2021.12Top 50 Most Innovative Companies of Chinese Biomedicine in 2021
2021.06 Excellent Roadshow Project of the 2nd Annual Meeting of Chinese Society of Cell Therapy of Zhangjiang International Summit on Cell Therapy Industry
2020.12The first prize of the 3rd Jiading District Entrepreneurship Competition in 2020
2020.122020 Jiading District Science and Technology Innovation Award
(arranged by alphabetic order)